Brookfield Corp’s IGM Biosciences IGMS Stock Holding History

Brookfield Corp’s Portfolio IGMS Stock Details IGMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-7,500	Closed	-$200K	–	668
2022 Q1	$200K	Buy	+7,500	New	+$140K	﹤0.01%	575

Other funds holding IGMS

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Brookfield Corp's IGMS Position: Q2 2022 in Review

Brookfield Corp sold out of IGM Biosciences (IGMS) in Q2 2022, closing a stake of 7,500 shares — an estimated $200K sold.

Brookfield Corp first reported a position in IGMS in Q1 2022 and held it in 1 quarter. The position peaked at $200K in Q1 2022. 89 funds tracked by Wall St. Rank hold IGMS as of Q2 2022.

Brookfield Corp reported no remaining IGM Biosciences position as of Q2 2022 after selling out during the quarter.
Brookfield Corp sold 7,500 IGM Biosciences shares in Q2 2022, an estimated $200K.
Brookfield Corp first reported a position in IGM Biosciences in Q1 2022 and held it in 1 quarter.
Brookfield Corp's IGM Biosciences position peaked at $200K in Q1 2022.
89 funds tracked by Wall St. Rank held IGM Biosciences as of Q2 2022.

Based on Brookfield Corp's 13F filing for Q2 2022, filed 15 Aug 2022.